Atlas Trials

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Clinical trial NCT01628913 · TERMINATED

Trial details

NCT number
NCT01628913
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Neuroendocrine Tumors (pNET)
Start date
2012-10-01
Primary completion
2014-09-01
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.